GlaxoSmithKline

-$0.75 (-1.85%) As of 5:44 PM UTC today

Why Robinhood?

You can buy or sell GSK and other stocks, options, and ETFs commission-free!

About GSK

GlaxoSmithKline plc, also called GlaxoSmithKline, is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare.

CEO
Emma N. Walmsley
Employees
94,066
Headquarters
Middlesex, Greater London
Founded
1999

GSK Key Statistics

Market Cap
99.63B
Price-Earnings Ratio
14.88
Dividend Yield
5.28
Average Volume
4.35M
High Today
$40.13
Low Today
$39.78
Open Price
$39.96
Volume
8.57M
52 Week High
$42.40
52 Week Low
$33.26

GSK News

Bloomberg20h

Glaxo-Backed Lyell Immunopharma Wobbles in Trading Debut

(Bloomberg) -- Lyell Immunopharma Inc., a cancer drug developer backed by GlaxoSmithKline Plc and Celgene Corp., seesawed in its trading debut after raising $42
MarketWatchJun 14

iTeos Therapeutics Shares Rise 32% on Deal With GlaxoSmithKline

By Chris Wack iTeos Therapeutics Inc. shares rose 32% to $26.54 after the company said it and GlaxoSmithKline Plc agreed to develop and commercialize EOS-448,
ReutersJun 14

GSK, iTeos to develop cancer drug in up to $2 bln deal

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo Britain

GSK Earnings

$0.00
$0.29
$0.58
$0.87
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Available Jul 28

More GSK News

MarketWatchJun 14

iTeos stock jumps 60% after company announces deal with GSK

Shares of iTeos Therapeutics Inc. ITOS, +0.86% soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline GSK, -0.20% t
BloombergJun 14

Glaxo Agrees to $2.1 Billion Cancer-Therapy Deal With iTeos

(Bloomberg) -- GlaxoSmithKline Plc will pay U.S. company iTeos Therapeutics Inc. as much as $2.1 billion to develop a potential immune therapy as the British dr
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure